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Background: Transforming growth factor-β (TGF-β) is a multi-factorial peptide growth factor that has a vital role in
the regulation of cell growth, differentiation, inflammation, and tissue repair. Quantification of biologically active
TGF-β levels in tissues is crucial to illustrate mechanisms involved in various physiological and pathological
processes, but direct measurement of bioactive TGF-β level in the tissue has been hampered by lack of reliable
methods. Here, we introduced mink lung epithelial cell bioassay to quantify both active and total TGF-β levels in
serum and protein lysates from solid organs in the mouse model.
Findings: Mink lung epithelial cells were stably transfected with plasminogen activator inhibitor-1 promoter/
luciferase construct, in which bioactive TGF-β level was represented by luciferase activity. Serum total TGF-β levels
were comparable between the bioassay and enzyme-linked immunosorbent assay (ELISA), but active TGF-β levels
measured by ELISA were significantly lower than those obtained by the bioassay. Active and total TGF-β levels in
the solid organs including heart, liver, and kidney were also measured. Total TGF-β levels were relatively
comparable among these organs, but active TGF-β levels were slightly higher in hearts and kidneys than in livers.
Positive luciferase activities in the bioassay were almost completely inhibited by adding pan-TGF-β neutralizing
antibodies, suggesting its high specificity to bioactive TGF-β. We also measured myocardial TGF-β levels after
myocardial infarction and sham control by the bioassay, and compared the values with those obtained by ELISA.
The bioassay demonstrated that both active and total tissue TGF-β levels were significantly higher in
post-myocardial infarction than in sham myocardium. ELISA was markedly less sensitive in detecting both active
and total TGF-β levels than our bioassay and failed to show any statistically significant difference in TGF-β levels
between myocardial infarction and sham myocardium.
Conclusions: Our data suggested that the bioassay was significantly more sensitive than ELISA in detecting active
TGF-β in serum and both active and total TGF-β in solid organ tissues. The bioassay will be useful in investigating
TGF-β profile in various solid organs in physiological and pathological conditions.
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Background
The transforming growth factor-β (TGF-β) superfamily
consists of more than 40 members including TGF-β, ac-
tivins, inhibins, growth differentiation factors, and bone
morphogenetic proteins. They regulate a variety of phys-
iological processes, including embryonic development,
cell proliferation, differentiation, migration, adhesion,
extracellular matrix (ECM) production, chemotaxis, ho-
meostasis, and wound healing [1-7]. Three TGF-β iso-
forms, TGF-β1, TGF-β2, and TGF-β3, are known. The
regulatory mechanisms of TGF-β activation process are
complex (reviewed in [8-10]). The TGF-β is synthesized
as an inactive protein, latent TGF-β, which consists of
TGF-β dimer, and a latency-associated peptide (LAP).
This small latent protein complex binds with the latent
TGF-β binding proteins (LTBP) and is anchored in the
insoluble ECM. The TGF-β is activated when a large
protein complex is released from ECM via proteolytic
cleavage. Dysregulation of the TGF-β pathway has been
implicated in many human diseases including neoplastic
[8,11], fibrotic [2,9], and cardiovascular diseases [10], but
TGF-β involvement in these pathological conditions is
complex and sometimes paradoxical [11,12].
Several methods have been developed and utilized to
assess TGF-β profile in the tissue. Tissue TGF-β profiles
can be assessed by mRNA and protein levels using real-
time reverse transcriptase polymerase chain reaction
(qRT-PCR) and immunoblots, respectively. Other ap-
proaches include nuclear localization of TGF-β or pSmad
protein by immunohistochemical assay [13,14], enzyme-
linked immunosorbent assay (ELISA) [15,16], and plas-
minogen activator inhibitor (PAI)-1 promoter/luciferase
assay using mink lung epithelial cells (MLEC) [17,18].
Quantification of TGF-β levels in biological fluids in-
cluding plasma, serum, and saliva has been reported;
whereas, reliable measurement of TGF-β in solid organ
tissues has been challenging because a substantial amount
of TGF-β is sequestrated in insoluble ECM. Previously,
ELISA has been used to measure total TGF-β1 levels in
some human tissues [15,16]. However, ELISA is limited
in its effectiveness of antigen-antibody response being
subject to multiple environmental parameters and its in-
ability to measure biologically active TGF-β.
In this study, we used a bioassay in which MLECs
were stably transfected with an expression construct
containing a truncated PAI-1 promoter fused to the fire-
fly luciferase reporter gene [17,18] to quantify both bio-
logically active and total TGF-β in serum, liver, heart,
and kidney tissue. We also compared TGF-β levels mea-
sured by MLEC bioassay and ELISA in serum and myo-
cardial tissues. Our results demonstrated that MLEC
bioassay was a very specific and highly sensitive method
to detect myocardial TGF-β levels when compared withcommercially available ELISA. In addition, we found that
serum TGF-β levels, even in normal control mice, were
markedly higher than previously reported [19,20] and
that only a small fragment of total serum TGF-β (ap-
proximately 1.5%) was biologically active. These findings
suggest that TGF-β is not only a local growth factor but
also plays a systemic endocrine role in regulating tissue
homeostasis and that the serum also serves as a large
reservoir for latent TGF-β in addition to tissue extracel-
lular matrix.Materials and methods
Reagents
The purchased reagents include human recombinant
TGF-β1 and protease inhibitor cocktail (Roche Diagnos-
tic, Indianapolis, IN), Tris Base, sodium fluoride and so-
dium ortho vanadate (Fisher Scientific, Pittsburgh, PA),
sodium pyrophosphate (decahydrate), sodium molybdate,
and sodium glycerophosphate (Sigma-Aldrich, St. Louis,
MO), and TGF-β1, 2, and 3 neutralizing antibody and
TGF-β1 ELISA kit (both R&D Systems, Minneapolis, MN).Cell culture and transfection
Mink lung epithelial cells (ATCC, Manassas, VA) were
cultured in minimum essential medium (MEM) (ATCC,
Manassas, VA) supplemented with 10% fetal bovine
serum (Invitrogen Life Technologies, Carlsbad, CA).
Mink lung epithelial cells are rapidly growing cells re-
quiring splitting (1:5) every two to three days. These
cells (7×105 cells) were seeded in a 10-cm dish. After 24
hours, cells were transfected with PAI-1 promoter-Luci-
ferase construct (generously provided by Dr. D.B. Rifkin,
New York University Medical Center) [21] by FuGENE-
6 transfection reagent (Roche Diagnostic, Indianapolis,
IN) according to the manufactures’ protocol. Once the
MLECs became confluent, cells were split and grown in
the presence of 400 μg/ml of Geneticin (Invitrogen, Life
Technologies, Carlsbad, CA) for stable clone selection.
Only transfected cells can survive in the presence of
Geneticin because the expression construct contains
neomycin-resistant gene. Twenty-four neomycin-resistant
colonies were picked and were separately grown in a 24-
well plate with Geneticin. These clones were expanded to
a 12-well plate, followed by a a 6-well plate, then T25
flasks, and finally T75 flasks in presence of 400 μg/ml
Geneticin. The clones were trypsinized, resuspended in
cryo medium (complete media plus 5% dimethyl sulfoxide
[DMSO]), and kept in liquid nitrogen. After testing the
clones for luciferase activity with human recombinant
TGF-β1, clone #22 was found most sensitive and was thus
used in all the ongoing experiments in presence of 250
μg/ml of Geneticin. The clone was used up to a maximum
of 30 passages.
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For measurement of TGF-β in serum and various solid
tissue organs including liver, heart, and kidney, C57BL/6
male mice 8 weeks of age were used. After mice were
euthanized with excessive CO2 inhalation, the blood,
liver, heart, and kidney were harvested under sterile con-
ditions. The blood samples were kept on ice and the
serum was isolated by centrifuge. For the MI study,
C57BL/6 male mice of 12 to 20 weeks old were used.
Non-reperfused experimental MI was performed by pro-
cedures described previously [22]. Briefly, under isoflur-
ane anesthesia (2%), the heart was exposed via small left
thoracotomy and suture ligation was placed immediately
distal to the bifurcation of the left anterior descending
artery with 6.0 silk sutures. Sham operation was per-
formed with the suture insertion at the same site of the
left ventricular free wall without suture ligation. After
two weeks, non-ischemic left ventricular myocardium
was dissected from post-MI and sham-operated mice
upon euthanization with excessive CO2 inhalation. All
animal procedures in this study were performed in ad-
herence with the National Institutes of Health Guidelines
on the Use of Laboratory Animals and were approved by
the Institutional Animal Care and Use Committee
(IACUC) of the Alfred I. duPont Hospital for Children.
Preparation of tissue extract
Isolated solid tissues were rinsed quickly in a sterile nor-
mal saline to remove the blood and were briefly placed
on a sterile cloth to let dry. The collected organs were
cut in small pieces, kept in cryo tubes on dry ice, and
subsequently stored at −70°C until further usage. To ob-
tain tissue lysates, approximately 30 to 50 mg of tissues
were minced and sonicated in 500 μl of lysis buffer (50
mM Tris–HCl pH 7.5) containing 100 mM sodium
fluoride, 30 mM sodium pyrophosphate, 2 mM sodium
molybdate, 1 mM sodium ortho vanadate, 1 mM glycer-
ophosphate, and 1x protease inhibitor cocktail on ice.
Samples were centrifuged at 13,000 rpm for 20 minutes
at 4°C. Clear supernatant was collected and stored in ali-
quots at −70°C. Protein quantification in the lysate was
done by the bicinchoninic acid (BCA) method [23].
Acid activation of serum and tissue extracts
To assess the amount of total TGF-β, acid activation
was performed with minor modification to isolate free
TGF-β molecules from latent complex [18]. Briefly, 30
μl of serum or protein lysate (equivalent to 100 to 300
μg protein) was added to 200 μl of MEM/bovine serum
albumin (BSA), followed by addition of 10 μl of 4 N
HCl. Samples were rocked for 1 hour at 4°C. Acid acti-
vation was stopped by neutralization with 10 μl of 4 N
NaOH. Once acid activated, the samples were stored on
ice and were used on the same day.Bioassay with MLECs
After being treated with trypsin, MLECs (4 ×104 cells)
were plated into a 96-well plate and incubated for three
hours at 37°C. First, different concentration (25 pg/ml to
100 pg/ml) of human recombinant TGF-β1 solutions in
200 μl of DMEM/BSA containing 250 μg/ml Geneticin
was plated in triplicates to obtain a standard luciferase
activity in response to bioactive TGF-β1. For active
TGF-β assay, 30 μl of serum samples were diluted with
220 μl of MEM/BSA (total 250 μl), which was further
diluted two times with MEM/BSA to a final volume of
500 μl. Twenty μl of these diluted serum samples were
again diluted with MEM/BSA containing 250 μg/ml
Geneticin to make a final volume of 200 μl, which were
transferred to a 96-well plate in triplicate replacing the
previous culture medium. The plate was incubated for
20 hours at 37°C and then harvested for luciferase assay.
For total serum TGF-β assay, samples were first acid-
treated as described above. Acid treated samples (250 μl)
were further diluted to a final volume of 5 ml MEM/
BSA to get luciferase reading in linear range. Twenty μl
of these diluted serum samples were added to a 96-well
plate in triplicate and final volume of the well was made
200 μl with MEM/BSA containing 250 μg/ml Geneticin.
Tissue TGF-β bioassay was performed similar to serum.
Instead of serum, 30 μl of tissue homogenate (equivalent
to 100 to 300 μg protein) were added to 220 μl of
MEM/BSA, which was further diluted up to a final 500
μl MEM/BSA. Twenty μl of the diluted sample was
added to a 96-well plate as above. All samples were
incubated for 20 hours. The tissue homogenate or serum
samples were diluted differently so that the active and
total TGF-β relative luciferase activity lies in the linear
range of standard curve.
Luciferase assay
After trypsinization, MLECs were replated into a 96-well
plate in 200 μl of MEM medium with 10% fetal bovine
serum (FBS) and incubated for 3 h at 37°C. All samples,
with or without acid activation, were incubated in
MEM/BSA in triplicate for 20 h at 37°C. Then, the cells
were harvested by adding 30 μl 1x passive lysis buffer
(Promega, Madison, WI) after washed with 1x phosphate
buffer saline (PBS). The plate was kept on rocker for five
minutes and then stored at −70°C before luciferase assay.
Luciferase assay reagent (100 μl: Promega, Madison, WI)
was added to each well by injector after being thawed in
a 37°C water bath and kept on rocker for five minutes.
The relative luciferase unit (RLU) was read by 2030
Multilabel Reader (Perkin Elmer, Waltham MA). Corre-
sponding TGF-β levels were calculated by subtracting
the RLU of control from the RLU of study samples be-
cause MLEC itself has endogenous TGF-β activity. The
TGF-β concentration was calculated with a standard
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represented as ng/ml, whereas the tissue TGF-β was
presented as ng/mg.
Inhibition of TGF-β by pan TGF-β neutralizing antibody
To test the specificity of PAI-1 promoter/luciferase re-
sponse to bioactive TGF-β, we measured luciferase levels
of the serum and liver homogenate with and without
TGF-β neutralizing antibody. Either 30 μl of serum or
liver homogenate (100 μg) was incubated with or with-
out 100 μg/ml TGF-β 1, 2 and 3 neutralizing antibody in
a final volume of 200 μl of MEM/BSA for two hours at
4°C while rocking followed by acid activation as de-
scribed in the previous section. These samples were then
used in a 96-well plate containing MLECs for luciferase
activity as described above.
Statistics
Graph-Pad Prism 5 software (GraphPad Software, San
Diego, CA) was used to compare the groups. One-way
analysis of variance with Newman-Keuls post test or two
tailed paired t-test were used to assess the significance
of data values. A p value of less than 0.05 is considered
as significant. All of the values were shown as mean ±
standard deviation unless indicated otherwise.
Results
Transforming growth factor β (TGF-β) assay using human
recombinant TGF-β1
In this study, we created new MLEC cell lines by trans-
fecting PAI-1/luciferase construct de novo. First, the luci-
ferase assay was performed with different concentrations
of highly pure (> 95%) human recombinant TGF-β1 to
obtain a standard dose-responsive curve. A consistent















Figure 1 Human recombinant TGF-β1 (hTGF-β1) - luciferase standard
incubated with various concentration of human recombinant TGF-β1 at 37
activity (RLU) by TGF-β1 between 0 and 0.1 ng/ml. The values represents m
cells, PAI=plasminogen activator inhibitor, RLU=relative luciferase unit, SD=repeatedly at TGF-β1 concentration from 0 to 100 pg/
ml corresponding 0 to 4000 RLU, at which range we
used to quantify TGF-β concentration (Figure 1). This
linear relationship was not consistent over 100 pg/ml. A
standard curve was obtained at each experiment to sim-
ultaneously quantify TGF-β concentration.
TGF-β levels in serum
It is known that TGF-β binds to a carrier protein, α2-
macroglobulin, in a non-covalent manner as a latent
form in the blood stream [24,25]. Active (= free) and
total (= free + latent) serum TGF-β levels were 2.1 ±
0.58 ng/ml and 136 ± 5.59 ng/ml, respectively, suggest-
ing that the level of the latent form of TGF-β is approxi-
mately 65 times higher than the active form in the blood
stream. In addition, we found that the total serum TGF-β
level was markedly higher than what was reported previ-
ously [19,20] (Figure 2A). The specificity of this bioassay
was previously confirmed in human and rat plasma [18].
We also tested the specificity of the bioassay in this
newly-created cell line. The inhibition of TGF-β-induced
RLU response in the serum was examined by adding
TGF-β1, 2, and 3 neutralizing antibodies to the sample,
as previously described. By adding pan TGF-β neutraliz-
ing antibodies, the measured serum TGF-β levels were
inhibited by 92%, suggesting its high specificity to bio-
active TGF-β (Figure 2B).
TGF-β bioassay in liver homogenate
We next measured active and total TGF-β levels in the
liver homogenate. The active and total TGF-β levels in
liver homogenate were 0.15 ± 0.10 ng/mg and 1.48 ±
0.07 ng/mg, respectively. In the liver, the total TGF-β
level was about 10-fold higher than the active TGF-β level
(Figure 3A). The specificity of the bioassay to hepaticy = 39188x + 14.28
R² = 0.9986
0.05 0.075 0.1
F-  1 (ng/ml)
curve. PAI-1 promoter/luciferase construct-transfected MLECs were
°C for 20 h. There is a strict dose-dependent increase in luciferase
ean ± SD of 5 individual experiments. MLECs=mink lung epithelial
standard deviation, TGF-β=transforming growth factor-β.
Figure 2 Active and total TGF-β levels in serum and inhibition of serum TGF-β by pan TGF-β neutralizing antibodies. A. Active and total
TGF-β levels in serum. B Inhibition of total serum TGF-β in the absence or presence of 100 μg/ml of pan TGF-β neutralizing antibodies. RLU was
inhibited by 92% with neutralizing antibody. Sample size: n = 6. NAB=neutralizing antibodies, RLU=relative luciferase unit, TGF-β=transforming
growth factor-β.
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ase activity was inhibited by adding TGF-β1, 2 and 3
neutralizing antibodies to the protein lysate of the liver,
as explained in the previous section. Again, luciferase
activity was inhibited by 97% by the neutralizing anti-
bodies, suggesting its high specificity even for hepatic
TGF-β (Figure 3B).
TGF-β bioassay of heart and kidney homogenates
Both active and total TGF-β levels in heart homogenate
were 0.92 ± 0.12 and 1.89 ± 0.17 ng/ml, respectively.
The total myocardial TGF-β was approximately two-fold
higher than the active form, as shown in Figure 4A. Ac-
tive and total TGF-β levels in kidney homogenate were
0.84 ± 0.10 and 1.36 ± 0.05 ng/mg, respectively. The
total TGF-β level in the kidney was only 60% higher
than the active form (Figure 4B). In the three differentsolid organ tissues (liver, heart, and kidney), total TGF-β
levels were relatively comparable; whereas, the active
form differed slightly among the organs.
Comparison of TGF-β levels measured by ELISA versus
MLEC bioassay in serum and heart
To compare the efficacy of our MLEC bioassay with that
of a commercially available ELISA kit (R&D Systems,
Minneapolis, MN), we measured both active and total
TGF-β levels in serum and in heart by the two methods.
The heart tissues include post-myocardial infarction
(MI) non-ischemic ventricular myocardium and that of
sham-operated mice at two weeks after an experimental
coronary artery ligation. The TGF-β is known to be up-
regulated after MI and is thought to play a principal role
in post-MI ventricular remodeling [26]. We examined
whether tissue TGF-β levels were increased in post-MI
Figure 3 Active and total TGF-β levels in liver homogenate and inhibition of liver TGF-β by pan TGF-β neutralizing antibodies. A. Active
and total TGF-β levels in liver. B Inhibition of total liver TGF-β in the absence or presence of 100 μg/ml pan TGF-β neutralizing antibody.
TGF-β level was 97% inhibited by neutralizing antibody. Sample size: n = 6. NAB=neutralizing antibodies, RLU=relative luciferase unit,
TGF-β=transforming growth factor-β.
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the sham operated hearts.
First, ELISA revealed comparable total TGF-β levels
with bioassay in serum (ELISA 138 ± 12 ng/ml, bioassay
135 ± 5.6 ng/ml) but showed significantly lower active
TGF-β levels in serum than bioassay (ELISA 0.92 ± 0.45
ng/ml, bioassay 2.1 ± 0.6 ng/ml). Secondly, both active
and total TGF-β levels in myocardial tissues by ELISA
were markedly lower than those by bioassay. By bioassay,
the active myocardial TGF-β levels in sham and MI mice
were 1.92 ± 0.12 ng/mg and 2.54 ± 0.59 ng/mg (p =
0.039), respectively. The total myocardial TGF-β levels in
sham and MI mice were 3.94 ± 0.69 ng/mg and 7.19 ±
1.41 ng/mg (p = 0.0087), respectively (Figure 5). ELISA
showed extremely low yield in both active (sham
0.00540 ± 0.00672 ng/mg; MI 0.0498 ± 0.0302 ng/mg)
and total TGF-β levels (sham 0.312 ± 0.096 ng/mg; MI0.510 ± 0.066 ng/mg) and failed to demonstrate any sig-
nificant increase of either active or total TGF-β levels in
the post-MI myocardium compared with the sham myo-
cardium. Our data illustrated that ELISA showed com-
parable sensitivity with MLEC bioassay only when
measuring total serum TGF-β levels, but that ELISA
showed exceedingly low yield in detecting both active
and total TGF-β in the myocardial tissue than did
MLEC bioassay.
Discussion
The purpose of this study was to measure TGF-β levels
in the serum and solid organ tissues of mice, including
myocardium after MI in comparison with sham. To do
this, we developed sensitive reporter assay using MLECs.
By using this bioassay, we were able to measure both ac-












































Figure 4 Active and total TGF-β levels in heart and kidney.
Active and total TGF-β levels in heart homogenate (A) and kidney
homogenate (B). Sample size: n = 6. TGF-β=transforming growth
factor-β.
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revealed much better sensitivity than ELISA not only in
solid organ tissues but also in serum. It is extremely ad-
vantageous to know both active and total TGF-β levels
simultaneously to better delineate how TGF-β is involved
in ordinary physiological conditions and pathogenesis of
various progressive disease processes.
This bioassay is not a new method but rather a well-
established method that has been used to measure TGF-β
in biological fluids and rat lung [17,18], but it has not
been applied to measure TGF-β levels in solid organs. It
is surprising that this method has not been widely used
over decades; recently, many investigators have used
ELISA to measure total TGF-β levels in serum and solid
organ tissues. We have slightly modified the original
method and measured TGF-β levels in serum as well assolid organ tissues. Our current modification includes a
newly transfected MLEC cell line, a narrower range of
standard dose-responsive relationship, and use of a more
purified recombinant TGF-β to create a more stringent
standard dose-responsive curve. Direct measurement of
TGF-β in solid organs has been challenging because of
complex involvement of TGF-β in both soluble and in-
soluble forms. The known available methods to assess ac-
tive TGF-β include semi-quantitative methods such as
using transgenic mice-containing green fluorescent pro-
tein under the control of TGF-β responsive element
(CAGA)12 [21,27], using specific antibodies to bioactive
TGF-β [28-30], or indirect measurements by antibodies
that recognize pSmad2 and pSmad3 [31-33]. Neverthe-
less, the direct measurement of bioactive TGF-β in the
tissues still remains a major challenge.
We took advantage of the MLEC bioassay system and
selected the standard curve in a very narrow range from
0 to 100 pg/ml in which biologically active TGF-β binds
to PAI-promoter to activate luciferase in a strict dose-
dependent manner. Commercially available ELISA are
commonly used to measure total TGF-β levels mostly in
serum, plasma, urine, and other biological fluids [34,35],
and sometimes in solid tissues [15,16,34]. Our data
showed that the sensitivity of ELISA and bioassay was
equal when measuring total serum TGF-β levels, but the
bioassay showed markedly higher sensitivity in both ac-
tive and total TGF-β levels in tissues than ELISA. At the
same time, this bioassay was also proven to be highly spe-
cific (Figures 2B and 3B). The advantage of ELISA is its
wide measurement range, whereas the disadvantage is
that the biological activity of the detected antigen is un-
certain, especially for active TGF-β [21] and poor sensi-
tivity when measuring solid organ tissues. The major
advantage of this bioassay is its ability to measure both
active and total TGF-β in serum and solid organs. Under-
standing both active and total TGF-β levels simultan-
eously would provide us with further insight into how
TGF-β is involved in physiological and pathological con-
ditions including chronic fibrotic disorders [2,9], heart
failure [36-38], and cancer progression [8,11].
Our current study also indicated that circulating blood
or serum serves as an enormous reservoir for bioactive
TGF-β. In this study, we elected to use serum instead of
plasma because plasma contains platelets, another major
source of TGF-β. The TGF-β levels in serum and platelet-
poor plasma in humans are known to be comparable
[19]. Our results not only demonstrated that the cir-
culating total TGF-β level was markedly higher than
what was reported previously [19,20] but also showed
that the majority of serum TGF-β exists as a latent form
with only a fraction being biologically active (1.6%). The
presence of latent complex as a predominant form of
circulating TGF-β suggests the endocrine role of TGF-β
Figure 5 Active and total TGF-β levels in sham and two weeks post-myocardial infarction (MI) mice left ventricular myocardium
measured by ELISA and bioassay. A: Active TGF-β levels and B: Total TGF-β levels in sham and two weeks post-MI heart homogenate. For both
sham and MI, bioassay revealed not only significantly higher TGF-β levels than ELISA (p < 0.05), but also showed significant increase of both
TGF-β levels in MI compared with sham (p < 0.05), whereas ELISA failed to show significant increase in MI compared with sham. Sample size:
n = 6. ELISA=enzyme-linked immunosorbent assay, MI=myocardial infarction, TGF-β=transforming growth factor-β.
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free TGF-β and its non-covalently binding the major
serum protein, α2-macroglobulin [25]. Circulating TGF-β
levels were noted to be elevated in multiple patholog-
ical conditions including breast cancer [40], non-small
cell lung cancer [41], hepatocellular carcinoma [42],
and dilated cardiomyopathy [43]. These TGF-β levels
were all total values measured by ELISA, but there has
been no study to address circulating bioactive TGF-β
levels in either physiological or pathological conditions.
With simultaneous measurement of active and total
TGF-β levels by the MLEC bioassay, we will be able to
obtain deeper insights into TGF-β biology and its in-
volvement as a biomarker in pathogenesis of various
disease processes.Conclusion
The MLEC bioassay is a useful and reliable method to
quantify both active and total TGF-β levels in both
serum and various solid organ tissues, and it can be used
to address more accurate TGF-β profiles in various
pathological conditions. Direct measurement of active
TGF-β levels in the tissue has never been well estab-
lished. Simultaneous measurement of both active and
total TGF-β levels in various pathological specimens
would help us understand the mechanism of progressive
disorders including fibrotic diseases, chronic inflamma-
tory disorders, heart failure, and cancers in clinical set-
tings. Our current data also suggest that TGF-β plays a
role not only as a local tissue growth factor but also as a
circulating hormone in both physiological and patho-
logical conditions. Our current method will open an ex-
citing new arena in studying TGF-β as an important
biomarker in numerous clinical situations.Abbreviations
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